Amylyx Pharmaceuticals Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative co...
Latest News
8 hours ago · businesswire.com
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.
21 days ago · schaeffersresearch.com
11 Stocks Most Likely to See a Short Squeeze RallyBond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
27 days ago · businesswire.com
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingCAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
1 month ago · schaeffersresearch.com
10 Stocks With Massive Short Squeeze PotentialBond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
2 months ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · fool.com
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This WeekAnalysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
2 months ago · gurufocus.com
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common StockAmylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (âAmylyxâ or the âCompanyâ) today announced the pricing of an upsized underwritten public offering of 14,090
3 months ago · zacks.com
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study WinAmylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
3 months ago · fool.com
Why Amylyx Pharmaceuticals Stock Skyrocketed TodayAmylyx is developing a GLP-1 treatment for people with chronic low blood sugar. The experimental therapy displayed a favorable safety profile in a clinical study.
3 months ago · businesswire.com
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common StockCAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are bein.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AMLX